Abstract
BackgroundCurrently, the progress of targeted drugs in the treatment of metastatic clear cell renal cell carcinoma (mccRCC) is limited. Cytoreductive nephrectomy (CN), as an alternative treatment, can improve the prognosis of patients with metastatic renal cell carcinoma to some extent. However, it is unclear which patients would benefit from this tumor reduction operation. As a consequence, we developed a predictive model to identify patients who may well benefit from CN in terms of survival.MethodsWe identified patients with metastatic clear cell renal cell carcinoma retrospectively from the Surveillance, Epidemiology, and End Results (SEER) database (2010–2015) and classified them into surgery and non-surgery groups. Propensity score matching (PSM) was performed to balance the baseline characteristics. Patients who survived longer than the median overall survival (OS) of no-surgery group were defined as surgical-benefit patients. Then, we developed a predictive model based on preoperative characteristics using multivariable Logistic regression. Calibration curves and the area under the receiver operating characteristic (AUC) were used to evaluate the efficiency of the predictive model. The clinical value of the nomogram was assessed utilizing decision curve analysis (DCA).ResultsOur study collected 5544 patients from the SEER database, with 2352(42.4%) receiving cytoreductive surgery. Overall survival (OS) was longer in the CN group than in the non-surgery group after 1:1 propensity scoring matching (median OS: 19 months vs 7 months; hazard ratio (HR) =0.4106, P< 0.001). In the matched surgery group, 65.7% (367) patients survived more than 7 months after the operation and they were considered to benefit from CN. The predictive model performed well on both the training group (AUC=73.4%) and the validation group (AUC=71.9%) and the calibration curves indicated a high degree of consistency. The decision curve analysis curve demonstrated the clinical utility. We classified surgical patients into the beneficial group and non-beneficial group by using the predictive model, then discovered a substantial difference in OS between the two groups.ConclusionsWe developed a nomogram to select ideal mccRCC patients who might benefit from cytoreductive nephrectomy. Clinicians could make a more precise treatment strategy for mccRCC patients.
Highlights
Renal cell carcinoma (RCC) is one of the most prevalent types of malignant tumor in the urinary system, accounting for 3% of all malignancies globally
After propensity scoring matching (PSM), we defined patients in the surgery group as “Surgicalbenefit” if their survival time exceeded the median Overall survival (OS) time of the non-surgery group; we classified patients in the surgery group as “beneficial group” and “nonbeneficial group” (Survival time ≤ 7months). We developed this prediction model by using multivariate logistic regression analysis to identify patients with Metastatic clear cell renal cell carcinoma (mccRCC) who may benefit from Cytoreductive nephrectomy (CN)
Based on multivariate Logistic regression analysis, we present a predictive model in the form of a nomogram to predict which mccRCC patients in the training group will benefit from CN (Figure 7)
Summary
Renal cell carcinoma (RCC) is one of the most prevalent types of malignant tumor in the urinary system, accounting for 3% of all malignancies globally. RCC is divided pathologically into 3 main types: clear cell renal cell carcinoma (ccRCC), papillary renal cell carcinoma (pRCC), and chromophobe renal cell carcinoma (chRCC). Among these types, ccRCC is the most prevalent histological subtype (about 80%) and has a poorer prognosis than pRCC and chRCC [1, 2]. Cytoreductive nephrectomy (CN), as an alternative treatment, can improve the prognosis of patients with metastatic renal cell carcinoma to some extent. It is unclear which patients would benefit from this tumor reduction operation. We developed a predictive model to identify patients who may well benefit from CN in terms of survival
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.